# Legend Biotech account plan

> Legend Biotech develops and makes CAR-T cell therapies, led by CARVYKTI with Janssen; FY2025 revenue $1,028.9 million, about 3,300 employees.

## At a glance

Legend Biotech is a Cayman Islands holding company that discovers, develops, manufactures and commercialises cell therapies for oncology, operating through subsidiaries in the United States, China and Europe, with principal offices in Somerset, New Jersey. Its one approved product, CARVYKTI (cilta-cel), is an autologous BCMA CAR-T for relapsed or refractory multiple myeloma, co-developed and co-commercialised with Janssen (Johnson & Johnson) on a 50/50 cost and profit split worldwide and 70/30 in Greater China. FY2025 total revenue was $1,028.9 million (FY2024: $627.3 million), with an operating loss of $136.5 million and a net loss of $296.8 million. The company had 2,965 employees at December 31, 2025 and now describes a team of approximately 3,300. Genscript owns about 47% of the shares.

## Business units

- **CARVYKTI franchise (collaboration revenue)** (about 92% of FY2025 revenue ($944.8 million)): Legend's share of CARVYKTI sales under the Janssen Agreement, $746.1 million from the United States and $198.7 million outside it in FY2025. Q3 2026 CARVYKTI net trade sales rose 36% to about $710 million across 373 treatment sites in 20 markets. Alan Bash is President, CARVYKTI.
- **License and other revenue** (about 8% of FY2025 revenue ($84.1 million)): Milestones from Janssen and licence revenue from the Novartis License Agreement for DLL-3 CAR-Ts including LB2102 ($100 million upfront, up to $1.01 billion of milestones). It fell from $144.7 million in FY2024 as Janssen milestones dropped to $4.9 million.
- **Pipeline (research and development)**: R&D of $414.7 million in FY2025, of which $215.6 million on non-BCMA programs: solid-tumour CAR-Ts (LB1908, LB2102), allogeneic gamma delta CAR-T and CAR-NK candidates, and in vivo CAR-Ts. LB2501, a CD19/CD20 in vivo CAR-T, received FDA IND clearance in 2026.
- **Manufacturing and supply**: 723 employees in global manufacturing and supply and 1,047 in quality/operations at end-2025. CARVYKTI is made in Raritan, New Jersey (leased from Janssen from February 2, 2026), by Novartis as a U.S. CMO and in two facilities in Ghent, Belgium; a GMP facility in Nanjing serves China.

## Strategic priorities

- **Maximise CARVYKTI**: CEO Ingrid Zhang's first priority; management keeps a $5 billion-plus peak potential, driven by earlier lines, frontline studies and global expansion. Second- and third-line patients were 50% of U.S. apheresis volume in Q3 2026, up from 29% in Q1 2025.
- **Next-generation pipeline, led by in vivo CAR-T**: LB2501 showed 100% ORR and CR at dose level 2 (8 patients); a U.S. Phase Ia will confirm dose before a Phase Ib across DLBCL, MCL and CLL. LB2505, a BCMA in vivo CAR-T, falls under the Johnson & Johnson agreement.
- **Sustained profitability**: Q2 2026 was the first quarter of company-wide profitability; the goal is full-year 2026 profitability on an adjusted net income basis, with double-digit CARVYKTI growth expected in 2027.
- **Gross margin expansion**: Gross margin reached 58% on manufacturing efficiencies; Q4 2026 is expected in the high 50% range, and the CFO sees "a clear path to 75%" over time.
- **Frontline readouts**: CARTITUDE-5 and CARTITUDE-6 are event-driven; CARTITUDE-5 could read out in 2027 at the soonest, with CARTITUDE-6 later.

## Latest results

In Q3 2026 total revenue was $359.5 million (Q3 2025: $272.4 million), of which collaboration revenue $353.2 million. Operating income was $46.8 million against an operating loss of $43.3 million a year earlier, and net income $51.7 million against a $39.6 million loss; adjusted net income was $55.6 million. R&D fell to $95.3 million as major cilta-cel trials finished dosing. Over nine months revenue was $1,052.1 million and net income $30.6 million, against a net loss of $266.0 million. The company gives no formal guidance, but the CFO said Q4 sales consensus sits at the higher end of internal scenarios and expects double-digit CARVYKTI growth in 2027.

## Investments and deals

- **Manufacturing capacity**: Capex was $69.3 million in 2025 and is expected to increase, mainly in the United States, the EU and China; under the Raritan Supply Agreement (effective February 2, 2026) Legend supplies cilta-cel to Janssen worldwide excluding Greater China at cost plus a markup.
- **June 2026 equity offering**: 7,700,000 ADSs at $29.35 per ADS raised net proceeds of about $211.6 million, described as opportunistic after the in vivo data and giving better business-development optionality.
- **Settling Janssen funding advances**: Janssen is recouping $319.1 million of funding advances and interest from Legend's profit share in 2026; the remaining advance was $44.1 million at September 30, 2026.
- **Collaboration assets prepayment**: Nine-month 2026 investing outflows included a $46.6 million prepayment to Janssen for collaboration assets and $20.6 million of property, plant and equipment.

## Challenges and risks

- **Dependence on one product and one partner**: The company depends on CARVYKTI's commercial success and on Janssen to market and sell it.
- **Competition from bispecifics and other BCMA therapies**: Management calls the space increasingly competitive, with strong uptake of bispecifics, including Janssen's own TECVAYLI, in earlier lines; U.S. earlier-line share growth was slower than anticipated.
- **Manufacturing complexity and suppliers**: Risks include manufacturing complexity and capacity, reliance on CMOs and a limited number of suppliers, including for lentiviral vectors.
- **Ex-U.S. launch timing**: The CFO cited ex-U.S. launch delays as one reason Q4 2026 consensus sits at the higher end of scenarios.
- **China and pricing exposure**: PRC legal, regulatory, data and currency risks, an advance pricing agreement still under negotiation with Chinese tax authorities, and U.S. drug pricing policies.

## What leadership says

> "We remain focused on disciplined execution, expanding access to CARVYKTI worldwide, advancing our innovative pipeline, and delivering sustained profitability." — Ingrid Zhang, Chief Executive Officer, Q3 2026 earnings release (Form 6-K), November 10, 2026

> "number one, maximize CARVYKTI; number two, advance our next-generation pipeline; and number three, strengthen execution on all fronts to deliver sustained profitability." — Ingrid Zhang, Chief Executive Officer, Q3 2026 earnings call, November 10, 2026, her first as CEO

> "it's really not about which product you choose, it's really about the sequence in which you offer them." — Alan Bash, President, CARVYKTI, Q3 2026 earnings call, November 10, 2026, on competition from bispecifics

> "This is a leadership transition, not a strategy transition. Our priorities remain unchanged." — Alan Bash, then Interim Chief Executive Officer, Q2 2026 earnings call, August 11, 2026


## Where a supplier can help

- **Manufacturing scale-up and efficiency**: With capex expected to rise and a gross margin target path towards 75%, suppliers of cell-therapy manufacturing equipment, automation and process consulting can support the Raritan, Ghent and Nanjing sites.
- **Supply-chain resilience for vectors and materials**: The stated reliance on a limited number of suppliers, including for lentiviral vectors, opens room for second-source material and logistics providers.
- **In vivo CAR-T clinical development**: The U.S. Phase Ia and Phase Ib plan for LB2501 points to needs for CRO, clinical-site and trial-data services as the pipeline becomes the second priority.
- **Commercial reach in earlier lines and new markets**: Growth depends on earlier-line uptake in the U.S. and new launches outside it; physician education, market-access and patient-support services fit the priority to maximise CARVYKTI.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 20-F for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm)

Annual report · 2026-03-10

- Legend Biotech is a Cayman Islands holding company operating through subsidiaries in the United States, the PRC and the EU, with about 2,900 employees (2,965 in the headcount table: 1,461 United States, 992 Europe, 512 Asia-Pacific) at December 31, 2025; principal offices in Somerset, New Jersey.
- It depends on one approved product, CARVYKTI (cilta-cel), an autologous BCMA CAR-T for relapsed/refractory multiple myeloma co-developed and co-commercialised with Janssen (Johnson & Johnson): 50/50 costs and pre-tax profits worldwide, 70/30 in Greater China.
- FY2025 total revenue was $1,028.9 million (FY2024: $627.3 million): collaboration revenue $944.8 million (up $462.2 million), license and other revenue $84.1 million (down from $144.7 million).
- The company remained loss-making: operating loss $136.5 million (FY2024: $309.5 million) and net loss $296.8 million, hit by $164.8 million of other expense, mostly unrealised FX losses on an intercompany loan and cash.
- R&D was $414.7 million: $199.1 million for the BCMA program and $215.6 million for non-BCMA programs, as pivotal BCMA trials wind down and pipeline spending rises; selling and distribution rose to $205.8 million.
- CARVYKTI reached a profitable position by end-2025, which triggers Janssen's recoupment in 2026 of $319.1 million of funding advances and interest from Legend's profit share.
- Pipeline beyond cilta-cel: autologous CAR-Ts in solid tumours (LB1908 Claudin 18.2, LB2102 DLL-3 licensed to Novartis), allogeneic gamma delta CAR-T and CAR-NK candidates, and an in vivo CD19/CD20 CAR-T for NHL in Phase 1 in China.
- Cash and cash equivalents, deposits and investment of about $948.6 million at December 31, 2025; capex was $69.3 million in 2025 and is expected to increase.
- Genscript owns about 47% of the shares; main risks are dependence on CARVYKTI and on Janssen, manufacturing complexity, competition in BCMA therapies and exposure to China.

### [Form 6-K: Financial Results for the Three and Nine Months Ended September 30, 2026 (press release and MD&A)](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000026/legn-20260930.htm)

Interim report · 2026-11-10

- Q3 2026 CARVYKTI net trade sales rose 36% year on year to about $710 million: U.S. up 19%, ex-U.S. up 86%; CARVYKTI is available in 373 treatment sites in 20 global markets.
- Total revenue was $359.5 million (Q3 2025: $272.4 million), of which collaboration revenue $353.2 million and license and other revenue $6.3 million.
- Operating income was $46.8 million versus an operating loss of $43.3 million; net income $51.7 million versus a net loss of $39.6 million; adjusted net income $55.6 million.
- R&D fell to $95.3 million as major cilta-cel trials finished dosing, partly offset by in vivo CAR-T spending; administrative expenses fell to $14.8 million on reversal of share-based compensation after forfeited awards.
- Nine months: revenue $1,052.1 million, net income $30.6 million (versus a net loss of $266.0 million), including $56.0 million of Janssen milestones.
- FDA cleared the IND for LB2501, a CD19/CD20 dual-targeting in vivo CAR-T for B-cell malignancies; five-year CARTITUDE-2 Cohort A data showed half of 20 patients alive and progression-free.
- Ingrid Zhang became CEO on September 15, 2026, succeeding interim CEO Alan Bash, who returned to President, CARVYKTI.
- Cash and time deposits were about $853 million at September 30, 2026 after a June offering with net proceeds of about $211.6 million; the remaining Janssen funding advance is $44.1 million.

### [Legend Biotech Q3 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/11/10/legend-biotech-legn-q3-2026-earnings-call-transcript/)

Executive talk · Ingrid Zhang, Chief Executive Officer · 2026-11-10

- Ingrid Zhang's first call as CEO: her priorities are "maximize CARVYKTI", advance the next-generation pipeline, and strengthen execution to deliver sustained profitability.
- Q3 CARVYKTI net trade sales rose about 36% to $710 million (U.S. +19%, ex-U.S. +86%) across 373 activated treatment sites.
- Second- and third-line patients were 50% of U.S. CARVYKTI apheresis volume in Q3 2026, up from 41% in Q1 2026 and 29% in Q1 2025.
- CFO Carlos Santos said Q4 sales consensus sits at the higher end of internal scenarios, citing ex-U.S. launch delays and slower U.S. earlier-line share growth; double-digit CARVYKTI growth is expected in 2027.
- Gross margin reached 58% on manufacturing efficiencies; Q4 gross margin is now expected in the high 50% range; the company stays on track for full-year 2026 profitability on an adjusted net income basis.
- Management keeps a $5 billion-plus peak potential for CARVYKTI; CARTITUDE-5 could read out in 2027 at the soonest.
- LB2501 in vivo CAR-T: 100% ORR and CR at dose level 2 (8 patients), no DLT or ICANS; U.S. Phase Ia to confirm dose, then Phase Ib across DLBCL, MCL and CLL.

### [Legend Biotech Q2 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/08/11/legend-biotech-legn-q2-2026-earnings-call-transcript/)

Executive talk · Alan Bash, Interim Chief Executive Officer · 2026-08-11

- Alan Bash, Interim CEO after Ying Huang stepped down as CEO and director: "This is a leadership transition, not a strategy transition"; priorities unchanged (maximize CARVYKTI, advance the pipeline, strengthen execution).
- Q2 2026 CARVYKTI net trade sales were about $657 million, up 50% year on year (U.S. +32%, ex-U.S. +128%) and up 10% on Q1; 348 global treatment sites across 19 markets.
- Q2 was the first quarter of company-wide profitability on both IFRS and adjusted bases: adjusted net income of $63 million, $0.16 per diluted share; operating margin of 15%.
- Second to fourth lines now exceed 70% of U.S. volume; outpatient use is about 60% of the mix, which changes gross margin dynamics.
- Gross margin on net product sales was 58%; CFO Carlos Santos expects Q3 in the lower 50% range and Q4 in the mid-50% range, and sees "a clear path to 75%" over time.
- A June equity offering raised about $212 million net, described as opportunistic after the EHA in vivo data; cash was about $965 million and the roughly $300 million J&J loan is being settled in 2026.
- LB2501 in vivo CAR-T: 100% ORR and 83.3% CR at dose level 2 in China; U.S. IND planned by year-end; LB2505 (BCMA in vivo) enters an investigator-initiated study in China.
- Tax rate expected in the high 20% range over the next several quarters as a China advance pricing agreement is negotiated.

## Questions about Legend Biotech

### What does Legend Biotech do?

Legend Biotech discovers, develops, manufactures and commercialises cell therapies. Its approved product, CARVYKTI, is a BCMA CAR-T for relapsed or refractory multiple myeloma sold with Janssen, and its pipeline includes in vivo and allogeneic CAR-Ts.

### What was Legend Biotech's revenue?

FY2025 total revenue was $1,028.9 million, up from $627.3 million in FY2024. Revenue for the first nine months of 2026 was $1,052.1 million.

### How many employees does Legend Biotech have?

It had 2,965 employees at December 31, 2025 (1,461 United States, 992 Europe, 512 Asia-Pacific) and now describes a team of approximately 3,300.

### Who leads Legend Biotech?

Ingrid Zhang became CEO on September 15, 2026, succeeding interim CEO Alan Bash, who returned to President, CARVYKTI. Carlos Santos Garcia is CFO, and Genscript co-founder Fangliang Zhang chairs the board.

### Is Legend Biotech profitable?

Q2 2026 was its first quarter of company-wide profitability, and nine-month 2026 net income was $30.6 million against a $266.0 million loss a year earlier. The goal is full-year 2026 profitability on an adjusted net income basis.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
